Onco-Innovations Ltd. ( (TSE:ONCO) ) has provided an update.
Onco-Innovations Limited announced promising results from a study on its second-generation nanoparticle formulation of Polynucleotide Kinase 3′-Phosphatase (PNKP) Compound, which demonstrated low toxicity and high safety in treating colorectal cancer in mice. This development suggests potential for safer and more effective cancer therapies, enhancing Onco-Innovations’ position in the oncology field and offering hope for stakeholders seeking advanced cancer treatment options.
More about Onco-Innovations Ltd.
Onco-Innovations Limited is a Canadian-based company focused on cancer research and treatment, specializing in oncology. The company aims to prevent and cure cancer through pioneering research and innovative solutions.
YTD Price Performance: 203.53%
Average Trading Volume: 420,504
Find detailed analytics on ONCO stock on TipRanks’ Stock Analysis page.